ClinicalTrials.gg
CompletedNCT03709628EBFIM117Updated Feb 2, 2021

A Study of a FimH Blocker, EB8018, in Crohn's Disease Patients

A Phase 1 interventional study of EB8018 (First-in-class FimH blocker) in Crohn Disease, sponsored by Enterome. Completed at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Enterome · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 316 studies in Crohn Disease with a site in France — 79 open to participants now, 103 under way, 29 of them phase 3. Crohn Disease · France.

Enrollment
225th of 228
8 · median 147
Started
2018
with 24 others
Phase 1
5 of 316
none open now
Registered
160th of 316
by date

Among the 316 studies in Crohn Disease with a site in France, this one is the 225th largest by enrollment of the 228 interventional ones that give a count, is one of 25 that started in 2018, is one of 5 in phase 1, and was the 160th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

79 of the 316 studies in Crohn Disease with a site in France are open now. Recruiting first, the newest first:

74 more — sign in →

All 79 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 316 studies in Crohn Disease with a site in France, or all of them as a file.
02

Study summary

Enterome small molecule drug EB8018 is a first-in-class FimH blocker to be studied in Crohn's disease patients. The proposed indication for EB8018, as an add-on therapy, will be the treatment of adult patients suffering from Crohn's disease.

Read the detailed description

This open-label, multicenter study will enroll 8 evaluable patients with active Crohn's disease and will consist of 2 parts. Part 1 will include 2 sentinel patients with a single dosing period followed by a 13-day multiple dosing period. Part 2 will include the 6 remaining patients with multiple dosing only. This Phase 1b study will investigate the PK, safety, preliminary effects of the gut microbiome, and inflammatory biomarkers of EB8018 following 13 days of consecutive BID oral dosing in patients with Crohn's disease.

Part 1 of this study will demonstrate a single oral dose of EB8018 that is safe and tolerable in patients with Crohn's disease and Part 2 of this study will characterize the PK profile when administered as multiple oral doses.

03

Conditions studied

  • Crohn Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Selection Criteria:

  • Male and female patients of nonchildbearing potential ≥18 years of age at screening and Day -1
  • Active Crohn's disease based on an elevated calprotectin at baseline.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Patients with active Crohn's disease

    EB8018: 3000 mg for the single dose in Part 1 (2 sentinel patients) and 1500 mg BID for multiple dose administration over 13 days in Parts 1 and 2 (2 sentinel patients and 6 remaining patients), oral.

    Drug: EB8018 (First-in-class FimH blocker)

Interventions

  • DrugEB8018 (First-in-class FimH blocker)

    Drug: EB8018 EB8018 is an orally administered, first-in-class, FimH blocker • In Part 1, a single oral dose of EB8018 3000 mg will be administered to the 2 sentinel patients in the morning on Day 1. In the multi-dose treatment period (part 1 and 2), multiple oral doses of EB8018 1500 mg will be administered to 2 + 6 patients BID (in the morning and evening) on Days 1 through 13.

    Also known as: EB8018

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum observed plasma concentration

    Time frame: Day1, Day13

  2. Tmax

    Time to maximum observed plasma concentration

    Time frame: Day1

  3. AUC0-24

    Area under the plasma concentration time curve from time 0 to 24 hours

    Time frame: Day1; Day13

  4. T1/2

    Terminal elimination half-life

    Time frame: Day1; Day13

Secondary outcomes

  1. AE

    Adverse events

    Time frame: Up to Day22

  2. RR

    Inter-Beat intervalle (sec)

    Time frame: Up to Day22

  3. QRS complex

    intervalle (sec)

    Time frame: Up to Day22

  4. QT

    duration (sec)

    Time frame: Up to Day22

  5. PR

    intervalle (sec)

    Time frame: Up to Day22

  6. HR

    Heart rate (bpm)

    Time frame: Up to Day22

  7. BP

    Blood pressure (mmHg)

    Time frame: Up to Day22

  8. RR

    Respiratory rate (breaths per minute)

    Time frame: Up to Day22

  9. Temp

    Temperature (C°)

    Time frame: Up to Day22

Other outcomes

  1. Gut Microbiome

    Overall gene richness and relative abundance of Bacteroidetes, Enterobacteriaceae, and Firmicutes from sequencing of stool samples.

    Time frame: Up to Day22

  2. Inflammatory Biomarkers

    C-reactive protein

    Time frame: Up to Day22

  3. Inflammatory Biomarkers

    Fecal calprotectin

    Time frame: Up to Day22

  4. CDAI score

    CDAI calculation will be dependent on the parameters recorded in the subjects' diary and the parameters assessed at clinic visit by the investigator.

    Time frame: Up to Day22

07

Study locations

5 sites
  • Medical University Vienna
    Wien, Austria
  • Hôpital Claude Huriez
    Lille, France
  • Hôpital de l'Archet 2
    Nice, France
  • Universitätsklinikum Schleswig-Holstein Campus Kiel
    Kiel, Germany
  • Istituto Clinico Humanitas
    Rozzano, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Nov 2019, 20 months.

Of 33 industry-sponsored phase 1 interventional studies under Crohn Disease, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 20 months is above that.

Counting every sponsor, half of 61 studies reached it within 22 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2018
First posted
Oct 17, 2018
StartActual
Mar 7, 2018
Primary completionActual
Nov 12, 2019
CompletionActual
Dec 4, 2019
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03709628
Lead sponsor
Enterome
Responsible party
Sponsor
First posted
Oct 17, 2018
Start date
Mar 7, 2018
Primary completion
Nov 12, 2019
Completion
Dec 4, 2019
Last update
Feb 2, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion